Testimony Opposing HB 3265 (340B Drug Pricing Mandate) 4.9.25

TAHP opposes House Bill 3265, which removes critical transparency tools from the 340B drug program and enables hospitals to inflate drug costs at the expense of employers and patients. By prohibiting health plans from requiring a billing modifier to identify discounted 340B claims, the bill conceals when hospitals are profiting off deeply discounted drugs—marking them up as much as 280% or more. The result is higher premiums and out-of-pocket costs for Texans, with no guarantee of community benefit. HB 3265 expands a program originally intended for the underserved into a profit engine that harms private coverage.

Click here to view TAHP’s testimony in response to HB 3265.

Become a Member

Membership with TAHP is an invaluable tool for integrating, building relationships, exchanging information and best practices, and promoting your services. You will be well-armed with the most timely and accurate information, strong relationships with key Texas leaders, and access to seasoned policy and regulatory experts.